Evolvere BioSciences - About the company
Evolvere BioSciences is a seed company based in Oxford (United Kingdom), founded in 2021 by Weronika Ślesak, Piotr Jedryszek and Adam Winnifrith. It operates as a Developer of next generation antibiotics using artificial intelligence models to outpace bacterial resistance. Evolvere BioSciences has raised $500K in funding. The company has 291 active competitors, including 120 funded and 45 that have exited. Its top competitors include companies like Spero Therapeutics, Nimbus Therapeutics and Generate Biomedicines.
Company Details
Developer of next generation antibiotics using artificial intelligence models to outpace bacterial resistance. The platform combines computational power with biological expertise to design novel protein structures that can evade bacterial resistance and precisely target pathogenic bacteria. It uses artificial intelligence combined with co evolutionary protein protein interaction datasets to forecast bacterial mutations and create antibiotics that precisely target pathogenic bacteria without harming beneficial microbes or human cells.
- Website
- evolverebiosciences.com
- Registered Address
- 17 COPPER BEECH VIEW,TONBRIDGE,ENGLAND,TN9 2HF
Key Metrics
Founded Year
2021
Location
Oxford, United Kingdom
Stage
Seed
Total Funding
$500K in 1 round
Latest Funding Round
Investors
Ranked
156th among 291 active competitors
Employee Count
5 as on Aug 31, 2026
Similar Companies
Legal entities associated with Evolvere BioSciences
Evolvere BioSciences is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
ĒVOLVERE BIOSCIENCES LTD CIN: 13396961 , United Kingdom, Active | May 13, 2021 | - | 1 (As on Dec 31, 2024) |
Sign up to download Evolvere BioSciences' company profile
Evolvere BioSciences's funding and investors
Evolvere BioSciences has raised a total funding of $500K over 1 round. Its latest funding round was a Seed round on 2024 for $*****. 1 investor participated in its latest round. Evolvere BioSciences has 1 institutional investor.
Here is the list of recent funding rounds of Evolvere BioSciences:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
2024 | 4231 | Seed | 6134 | 3806 | 6033 | 6023 |
Access funding benchmarks and valuations. Sign up today!View details of Evolvere BioSciences's funding rounds and investors
Evolvere BioSciences' founders and board of directors
Founder? Claim ProfileHere are the details of Evolvere BioSciences' key team members:
- Weronika Ślesak: Co-Founder of Evolvere BioSciences.
- Piotr Jedryszek: Co-Founder & Director of Evolvere BioSciences.
- Adam Winnifrith: Co-Founder of Evolvere BioSciences.
View details of Evolvere BioSciences's Founder profiles and Board Members
Evolvere BioSciences' employee count trend
Evolvere BioSciences has 5 employees as of Aug 26. Here is Evolvere BioSciences's employee count trend over the years:
Uncover Evolvere BioSciences' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Evolvere BioSciences's Competitors and alternates
Top competitors of Evolvere BioSciences include Spero Therapeutics, Nimbus Therapeutics and Generate Biomedicines. Here is the list of Top 10 competitors of Evolvere BioSciences, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Spero Therapeutics 2013, Cambridge (United States), Public | Developer of therapeutics for drug-resistant bacterial infections | $115M | 69/100 | |
2nd |  Nimbus Therapeutics 2009, Cambridge (United States), Series F | Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases | $637M | 68/100 | |
3rd |  Generate Biomedicines 2018, Somerville (United States), Public | Developer of a platform for generating novel protein-based therapeutic modalities | $693M | 66/100 | |
4th | Locus Biosciences 2015, Raleigh (United States), Series B | Developer of therapeutics for infectious disease and inflammatory indications | $67.3M | 64/100 | |
5th |  Cradle 2021, Zurich (Switzerland), Series B | Provider of chemoproteomics solutions for protein design and development | $103M | 64/100 | |
6th |  EvolutionaryScale 2023, New York City (United States), Seed | Provider of an AI models for protein design | $142M | 64/100 | |
7th |  Profluent Bio 2022, Berkeley (United States), Series B | Provider of an artificial intelligence-based protein design platform | $150M | 64/100 | |
8th | LimmaTech Biologics 2015, Schlieren (Switzerland), Acquired | Developing bioconjugate vaccines using glycoengineering and protein glycosylation techniques | $40M | 63/100 | |
9th | Frontier Medicines 2018, San Francisco (United States), Series C | Developer of a bioinformatics platform for drug development and chemoproteomics | $236M | 62/100 | |
10th |  Eikon 2019, Millbrae (United States), Public | Protein tracking and measuring tool for drug discovery | $1.16B | 62/100 | |
156th |  Evolvere BioSciences 2021, Oxford (United Kingdom), Seed | Developer of next generation antibiotics using artificial intelligence models to outpace bacterial resistance | $500K | 31/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Evolvere BioSciences's competitors? Click here to see the top ones
Evolvere BioSciences's Investments and acquisitions
Evolvere BioSciences has made no investments or acquisitions yet.
Reports related to Evolvere BioSciences
Here is the latest report on Evolvere BioSciences's sector:
Are you a Founder ?
FAQs about Evolvere BioSciences
Explore our recently published companies
- Arthur Trusov - 2020 founded, Unfunded company
- STNF - San Jose based, 2020 founded, Unfunded company
- Ant Murphy - Unfunded company
- Haiti levage - 2021 founded, Unfunded company
- Graves Light Lenhart - Harrisonburg based, Unfunded company
- DonAndre - Italy based, Unfunded company
